Skip to main content

Profile: Sang Cho

Sang Cho
Sang Kyu Cho, Pharm.D., MPH, Ph.D. 
Assistant Professor of Pharmaceutical Health Outcomes and Policy

Health 2
University of Houston College of Pharmacy
4849 Calhoun Road, Room 4053
Houston, TX 77204-5047

Education

Ph.D. in Health Economics, University of Southern California, Los Angeles, CA

M.S. in Regulatory Management, University of Southern California, Los Angeles, CA

AbbVie HEOR Fellowship, North Chicago, IL

MPH in Health Policy and Management, Columbia University, New York, NY

Pharm.D., St. John’s University, Queens, NY

Research Interests

• Economic evaluation of pharmaceutical products and medical interventions

• Health Policy Simulation

• Data Analysis using electronic health records

• Opioids, Cancer, Alzheimer's disease, and Chronic Wounds

Publications

Peer-reviewed Publications

How much should a disease-modifying therapy for Alzheimer’s disease cost? A cost-effectiveness analysis (under review) Jun HK, Cho SK, Aliyev ER, and Suen SC

Budget Impact of 12-month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients in the United States. Cho SK, Manzoor BS, Sail KR, Parise H, Ravelo A, Shapouri S, Kapustyan T, Sharmokh S, Virabhak S, Davids S, and Johnson S. Pharmacoeconomics. 2020 May 8. doi: 10.1007/s40273-020-00919-1. Online ahead of print. PMID: 32383129

Development of a model to predict the healing of chronic wounds within twelve weeks (accepted for publication; Advances in Wound CareCho SK, Mattke S, Gorden H, Sheridan M, and Ennis W

Comment on Association of Optimism With Cardiovascular Events and All-Cause Mortality Systematic Review and Meta-analysis: Can Real World Evidence Capture Lifestyle and Life Attitude Effects Accurately? The Effects of Optimism on Cardiovascular and Mortality Risk. JAMA Network Open. 2019;2(9):e1912200. Gong C, Cho SK, Zawadzki R, Tran J, Grazette L, Zawadzki NK, and Hay JW

Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States. Cho SK, McCombs J, Punwani N, and Lam J. Leuk Lymphoma. 2019 Oct;60(10):2464-2470. doi: 10.1080/10428194.2019.1581932. Epub 2019 Mar 8. PMID: 30848975

Cost-effectiveness of regorafenib versus TAS-102 in refractory metastatic colorectal cancer in the United States. Cho SK, Hay JW, and Barzi A. Clinical Colorectal Cancer. 2018 Dec;17(4):e751-e761.

Presentations

Conference Presentations

Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer. Barzi A,Cho SK, Hay JW, Lenz HJ, Ou FS, Grothey A, Bekaii-Saab TS. Journal of Clinical Oncology 37 (15_suppl), e18367-e18367 (2019).

Factors impacting treatment selection in treatment-naïve patients with CLL: a multicenter study. Rhodes J, Sail K, Yazdy MS, Hill B, Shadman M, Tuncer H, Winter A, Kennard K, Allan J, Ujjani C, Brander D,Cho SK, Sharmokh S, Jiang DF, Nabhan C, Barr P, Brown J, Fox C, Schuh A, Eyre T, Lamanna N, Wierda W, Skarbnik A, Roeker L, Bannerji R, Evens A, Pauff J, Schuster S, Follows G, Cheson B, Eichhorst B, Mato A. European Hematology Association Congress, Amsterdam, Netherland (2019).

Total cost of care and budget impact for patients with CLL treated with venetoclax. Cho SK, Samp JC, Keim H, Masaquel AS, Johnson SJ, and Parise H. International Society of Pharmacoeconomics and Outcomes Research, Barcelona, Spain (2019).

Cost-effectiveness of regorafenib versus TAS-102 in refractory metastatic colorectal cancer. Cho SK, Hay JW, and Barzi A. International Society of Pharmacoeconomics and Outcomes Research, Baltimore, MD (2018).

Inpatient cost and complications of hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Cho SK, McCombs J, and Punwani N. International Society of Pharmacoeconomics and Outcomes Research, Baltimore, MD (2018).

Risk prediction model of 30-day hospital readmissions for patients with heart failure. Kudryashov D, Bae YH, Cho SK, and McCombs J. American Society of Health-Systems Pharmacists, Orlando, FL (2017).

Inpatient cost and complications of hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Cho SK, McCombs J, and Punwani N. Western Pharmacoeconomics and Outcomes Research Conference, Albuquerque, NM (2017).

Cost-effectiveness of regorafenib versus TAS-102 in refractory metastatic colorectal cancer. Cho SK, Hay JW, and Barzi A. Western Pharmacoeconomics and Outcomes Research Conference, Albuquerque, NM (2017).

A microwave imaging system and real-time image reconstruction algorithm for intraoperative 3D monitoring of thermal ablation therapies. Chen G, Stang J, Shah P, Cho SK, Leuthardt E, and Moghaddam M. Radiology Society of North America Annual Meeting, Chicago, IL (2017).

Memberships

Memberships
  • Member, International Society of Pharmacoeconomics and Outcomes